Skip to main content
. 2023 Mar 23;28(8):714–721. doi: 10.1093/oncolo/oyad039

Table 5.

Best response by RECIST 1.1 and irRECIST in patients with hepatocellular cancer with chronic viral hepatitis (n = 27).

Best overall response N (%)
Complete response 0
Partial response 1 (3.7)
Stable disease 12 (44.4)
Progression of disease 13 (48.1)
Not evaluable 1 (3.7)